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Background: Revision of the guidelines on the use of skin biopsy in the diagnosis of
peripheral neuropathy, published in 2005, has become appropriate owing to publi-
cation of more relevant articles. Most of the new studies focused on small ﬁber neu-
ropathy (SFN), a subtype of neuropathy for which the diagnosis was ﬁrst developed
through skin biopsy examination. This revision focuses on the use of this technique to
diagnose SFN.
Methods: Task force members searched the Medline database from 2005, the year of
the publication of the ﬁrst EFNS guideline, to June 30th, 2009. All pertinent articles
were rated according to the EFNS and PNS guidance. After a consensus meeting, the
task force members created a manuscript that was subsequently revised by two experts
(JML and JVS) in the ﬁeld of peripheral neuropathy and clinical neurophysiology,
who were not previously involved in the use of skin biopsy.
Results and Conclusions: Distal leg skin biopsy with quantiﬁcation of the linear
density of intraepidermal nerve ﬁbers (IENF), using generally agreed upon counting
rules, is a reliable and eﬃcient technique to assess the diagnosis of SFN (Recom-
mendation Level A). Normative reference values are available for bright-ﬁeld
immunohistochemistry (Recommendation Level A) but not yet for confocal immu-
noﬂuorescence or the blister technique. The morphometric analysis of IENF density,
either performed with bright-ﬁeld or immunoﬂuorescence microscopy, should
always refer to normative values matched for age (Recommendation Level A). Newly
established laboratories should undergo adequate training in a well-established
skin biopsy laboratory and provide their own stratiﬁed for age and gender
normative values, intra- and interobserver reliability, and interlaboratory agreement.
Quality control of the procedure at all levels is mandatory (Good Practice Point).
Procedures to quantify subepidermal nerve ﬁbers and autonomic innervated struc-
tures, including erector pili muscles, and skin vessels, are under development but
need to be conﬁrmed by further studies. Sweat gland innervation can be examined
using an unbiased stereologic technique recently proposed (Recommendation Level B).
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A reduced IENF density is associated with the risk of developing neuropathic pain
(Recommendation Level B), but it does not correlate with its intensity. Serial skin
biopsies might be useful for detecting early changes of IENF density, which predict the
progression of neuropathy, and to assess degeneration and regeneration of IENF
(Recommendation Level C). However, further studies are warranted to conﬁrm its
potential usefulness as an outcome measure in clinical practice and research. Skin
biopsy has not so far been useful for identifying the etiology of SFN. Finally, we
emphasize that 3-mm skin biopsy at the ankle is a safe procedure based on the
experience of 10 laboratories reporting absence of serious side eﬀects in approximately
35 000 biopsies and a mere 0.19% incidence of non-serious side eﬀects in about
15 years of practice (Good Practice Point).
Objectives
This document is written under the auspices of the
European Federation of Neurological Societies (EFNS;
http://www.efns.org) and the Peripheral Nerve Society
(PNS; http://www.pnsociety.com). The purpose is to
revise the guidelines on the use of skin biopsy in the
diagnosis of peripheral neuropathy [1]. In the last
4 years, a considerable number of new articles have
been published. These are mainly focused on small ﬁber
neuropathy (SFN). The role of skin biopsy as a diag-
nostic tool was analyzed in the evidence-based review
of the American Academy of Neurology, American
Association of Neuromuscular and Electrodiagnostic
Medicine, and American Academy of Physical Medi-
cine and Rehabilitation [2]. As skin biopsy retains a
particular interest in clinical practice for the diagnosis
of SFN, we focused the present guidelines on this
speciﬁc subtype of neuropathy.
The revision includes recommendations on: (i)
methods; (ii) safety; (iii) normative reference values; (iv)
diagnostic yield; (v) correlation with other measures of
neuropathy; (vi) use as outcome measure; (vii) EFNS/
PNS standards; (viii) new studies to address unresolved
issues.
Search strategy
The task force systematically searched the Medline
database from 2005, the year when the ﬁrst EFNS
guidelines were published [1], to June 30th, 2009. For
each speciﬁc issue, we stored all the articles published
in English sorted by the Medline search using the
following keywords: skin biopsy, punch biopsy, SFN,
painful neuropathy, normative values, intraepidermal
nerve ﬁbers (IENF), cutaneous innervation, and skin
nerves. We omitted those articles that were not perti-
nent, read and rated the remaining articles according to
the guidance for EFNS guidelines [3] and objectives of
the current article. In some cases, investigators were
asked for original data and methodological details.
Method for reaching consensus
Data extraction was carried out and compared amongst
each member of the task force. A ﬁrst draft of the
manuscript was prepared and diﬀused amongst the
members of the task force. After revision, a second
draft was prepared. Discrepancies on each topic were
further discussed and settled during a consensus meet-
ing held in Wu¨rzburg on July 7th, 2009. The third draft
of the manuscript prepared after the consensus meeting
was revised by an expert member of the task force
(W.R. Kennedy) and two experts in the ﬁeld of
peripheral neuropathy (J.M. Leger) and clinical neu-
rophysiology (J. Valls-Sole´) not directly involved in the
use of skin biopsy. The ﬁnal version of the guideline is
presented here.
Definition of small fiber neuropathy
Deﬁnitions of SFN have been proposed and used by
various authors [4–17], but conclusive diagnostic criteria
are not yet available. However, the most recent articles
focusing on the clinical applications of skin biopsy in
SFN used similar inclusion criteria for patients, based
on normal sural nerve conduction study (NCS), clini-
cal symptoms, and signs considered suggestive and/or
altered quantitative sensory testing (QST) ﬁndings. The
authors provided data on sensitivity and sensibility,
from which we derived our level of recommendations.
Methodological issues
How to perform skin biopsy and choice of biopsy
location
Skin biopsy is most commonly performed using a 3-mm
disposable punch under sterile technique, after topical
anesthesia with lidocaine. No suture is required. A
shallow biopsy (3–4 mm) is adequate to study epider-
mal nerve ﬁbers, whereas a deeper biopsy (6–8 mm) is
required to include sweat glands, hair follicles, and
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artero-venous anastomosis. To optimize the sampling
of such structures and of myelinated ﬁbers in hairy skin,
particular attention should be paid to include a hair in
the specimen [18].
Earlier studies were performed in healthy subjects
[19] and in patients with leprosy and diabetic neurop-
athy [20,21]. The current technique was developed at
the Karolinska Institute [22], and later standardized at
the University of Minnesota [23] and at the Johns
Hopkins University [24].
A less invasive sampling method is the removal of
the epidermis alone by applying a suction capsule to
the skin. With this method, there is no bleeding, and
local anesthesia is not needed. However, the method
does not provide information on dermal and sweat
gland nerve ﬁbers. Moreover, thus far it has not been
systematically used to investigate patients with SFN.
This technique was developed at the University of
Minnesota [25].
In most studies, hairy skin biopsies were obtained
from the distal part of the leg (10 cm above the lateral
malleolus), in some from the calf and the paraspinal
region, and in many of them also from the upper lateral
aspect of the thigh (20 cm below the anterior iliac spine)
or other proximal locations where normal values are
available. These locations were chosen to detect the
length-dependent loss of nerve ﬁbers, which is typical of
axonal polyneuropathy. These sites may also be sam-
pled in the case of a non-length-dependent ganglion-
opathy. More details are provided in Appendix 1.
Recommendations
For diagnostic purposes in length-dependent SFN, we
recommend that a 3-mm punch skin biopsy be
performed at the distal leg (10 cm above the lateral
malleolus) for quantiﬁcation of IENF density (Re-
commendation Level A). An additional biopsy from the
proximal thigh may provide information about both
length-dependent and non-length-dependent processes
(Recommendation Level C). When biopsy is taken from
other body sites for evaluation of a unilateral process, a
control biopsy from a similar non-aﬀected region
should be taken (Good Practice Point).
Tissue preparation
After skin biopsy is performed, the specimen is imme-
diately ﬁxed in cold ﬁxative for approximately 24 h at
4C, then kept in a cryoprotective solution for one
night, and serially cut with a freezing microtome or a
cryostat. Each biopsy yields about 50 vertical 50-lm
sections. The ﬁrst and last few sections should not be
used for nerve examination because of possible arte-
facts. Most studies for bright-ﬁeld microscopy used 2%
paraformaldehyde-lysine periodate (2% PLP), whereas
most studies for indirect immunoﬂuorescence with or
without confocal microscopy used Zambonis (2%
paraformaldehyde, picric acid) ﬁxative.
Either bright-ﬁeld immunohistochemistry or immu-
noﬂuorescence with or without confocal microscopy
has been used, but the technique does not aﬀect the
reliability of skin biopsy in assessing IENF loss in SFN
[1]. However, no study has been designed yet to com-
pare the two techniques. More details are provided in
the Appendix 1.
IENF morphometry and measurement reliability
Quantiﬁcation of IENF density using bright-ﬁeld
immunohistochemistry was mostly based on the
assessment of the number of ﬁbers per linear measure-
ment. Signiﬁcant correlation with a stereologic tech-
nique [26] supported the reliability of linear IENF
density [27]. IENF are counted either under the light
microscope at high magniﬁcation (i.e. 40· objective) or
using software for image analysis. The length of the
epidermal surface is measured using software for bio-
logical measures (a freely available software is available
at http://rsb.info.nih.gov/nih-image/index.html). The
density is calculated in at least three sections as the
number of IENF per length of the section (IENF/mm).
Other studies reported the IENF density per skin sur-
face area [28,29].
Quantiﬁcation of IENF density using confocal
immunoﬂuorescence technique is usually performed on
images based on the stack of consecutive 2 lm optical
sections (usually 16 sections) for a standard linear length
of epidermis. The thickness of skin sections varies from
32 to 60 lm. Four epidermal areas are selected for con-
focal image acquisition, two images on each of two dif-
ferent sections excluding areas containing hair follicles
and sweat ducts. For quantitative analysis, IENF are
counted at high magniﬁcation, (i.e. 40· objective) for
light microscope or (20·) for epiﬂuorescence microscope
or using a software for image analysis (e.g. Neurolucida,
Microbrightﬁeld) on digitized confocal images. Other
semi-quantitative methods of IENF density estimation
have been previously suggested [1].
In both bright-ﬁeld and immunoﬂuorescence meth-
ods, single IENF crossing the dermal–epidermal junc-
tion are counted, whereas secondary branching is
excluded from quantiﬁcation. No study provided
information on the rules for counting IENF fragments,
which have been comprehensively reviewed by Kennedy
et al. [30]. Intra- and interobserver variability, and
interlaboratory agreement on IENF counts has been
assessed [16].
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The skin blister is an alternative technique to assess
the epidermal innervation density. IENF density in
blister roofs from foot and calf correlated with IENF
density in skin biopsies from adjacent areas in 25
healthy subjects (r = 0.64 and r = 0.57, respectively)
showing no systematic diﬀerences between skin blisters
and biopsies (P = 0.29) or between pairs of blisters
from the same location (P = 0.15) [29]. More details
are provided in Appendix 1.
Recommendations
For diagnostic purposes, we recommend bright-ﬁeld
immunohistochemistry or immunoﬂuorescence with
rabbit polyclonal anti-PGP 9.5 antibodies in 2% PLP
or Zambonis ﬁxed sections of 50-lm thickness. For
methodological issues on bright-ﬁeld immunohisto-
chemistry, we refer to McCarthy et al. [24], on immu-
noﬂuorescence to Wang et al. [22], and on confocal
microscopy to Kennedy and Wendelschafer-Crabb [23].
IENF should be counted at high magniﬁcation in at
least three sections per biopsy. We emphasize that only
single IENF crossing the dermal–epidermal junction
should be counted, excluding secondary branching
and fragments from quantiﬁcation. The length of
the section should be measured to calculate the
exact linear epidermal innervation density (IENF/mm)
(Recommendation Level A). Adequate training in a
well-established skin biopsy laboratory is needed.
Further studies are warranted to establish the reliability
of the blister technique (Recommendation Level C) for
quantiﬁcation of IENF density in SFN.
Quantification of sweat gland innervation
The quantiﬁcation of sudomotor nerve ﬁbers is tech-
nically challenging because of the complex three-
dimensional structure of the sweat glands. Diﬀerent
methods have been proposed but none has been
standardized [1]. Novel methods using an unbiased
stereologic technique and automated technique for
quantiﬁcation of sudomotor nerve ﬁbers have been
recently proposed [31,32]. More details are provided in
Appendix 1.
Recommendations
Morphometric data on sweat gland innervation density
in healthy subjects and in patients with SFN are limited,
and further studies are warranted. The descriptive
semiquantitative approach should not be used to
quantify sweat gland innervation (Recommendation
Level B). The unbiased stereologic technique recently
proposed could be a helpful tool (Recommendation
Level B).
Safety
No side eﬀects have been reported in published studies
but no study focused on safety was performed. The
approximate number of biopsies performed with
3-mm disposable punch and side eﬀects recorded (in
parentheses) in healthy subjects and patients with
neuropathy of diﬀerent etiology in the 10 laboratories
participating in this guideline are Milan 1600 (2); Telese
Terme 2000 (2); Taiwan 1700 (1); Maastricht 300 (0);
Utah 2000 (3); Stockholm 1000 (0); Minneapolis 10 000
(3); Wu¨rzburg 800 (10); Tromsø 600 (1); Johns Hopkins
University 15 000 (44). The most common side eﬀect
was a mild infection because of improper wound
management recovering with topical antibiotic therapy.
The only other complication reported was excessive
bleeding which did not need suture. The estimated
frequency of side eﬀects is 1.9:1000. However, this ﬁg-
ure may be underestimated because patients with a
milder infection could have it treated by a general
practitioner or treat themselves without reporting to the
centre. Healing occurs within 7–10 days.
Recommendations
Skin biopsy performed with 3-mm disposable punch is a
safe and minimally invasive procedure based on the
experience of the 10 established laboratories reported
here. It requires training and is safe as long as sterile
procedures and hemostasis are correctly performed
(Good Practice Point).
Normative reference values
Bright-field immunohistochemistry
After the publication of the ﬁrst guidelines on skin
biopsy, three further large studies [7,16,33] estimated
the density of IENF at the distal leg (10 cm above the
lateral malleolus) in healthy subjects. Overall, including
all previously cited articles [1], values ranged
from 13.8 ± 6.7/mm (mean ± SD) to 9.8 ± 3.6/mm
(mean ± SD).
The largest normative study [16] included 188 healthy
subjects from three diﬀerent laboratories (Maastricht,
Ferrara, Milan) and stratiﬁed the study population per
age and gender, providing normative values per decade.
The authors reported that IENF density at the distal leg
is lower in men than in women, that weight and height
do not have any signiﬁcant impact, and that values
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decline with age (Table 1), thus conﬁrming previous
observations [34–36].
Immunofluorescence technique
No study speciﬁcally assessed the normative range of
IENF density at the distal leg using indirect immuno-
ﬂuorescence with or without confocal microscopy.
Overall, values obtained with confocal microscopy were
higher than those found using light microscopy tech-
nique. Normal values were reviewed by Kennedy et al.
[30]. Data from 267 healthy subjects included in 17
studies performed with and without confocal micros-
copy [29,37–52], ranged between 7.6 ± 3.1 and
33 ± 7.9/mm (mean ± SD) in subjects aged 20–
59 years. Density of 20.1 ± 5/mm (mean ± SD) was
found in subjects over 60 years (lower 5th percen-
tile = 11.8).
Blister technique
Panoutsopoulou et al. [29] reported the normative val-
ues of IENF density (expressed by number of IENF per
epidermal surface area) using both blister technique and
punch biopsy with confocal immunoﬂuorescence
microscopy at foot and calf in 25 healthy subjects (age
35–62 years). Mean IENF density on the foot was 174
IENF/mm2 for the punch biopsy and 162 IENF/mm2
for the blister method. Mean IENF density on the calf
was 158 IENF/mm2 for the punch biopsy and 143
IENF/mm2 for the blister method. Intra- and inter
blister variability was less than intrabiopsy variability.
The authors found a signiﬁcant correlation between the
two techniques.
Recommendations
Normative reference values must consider that IENF
density at the distal leg (10 cm above the lateral
malleolus) declines with age (Recommendation Level
A) and may be lower in men than in women. However,
it is not inﬂuenced by weight and height. Normative
reference values are available for bright-ﬁeld immu-
nohistochemistry (Recommendation Level A) but not
yet for confocal immunoﬂuorescence or blister tech-
nique.
Diagnostic yield of skin biopsy
In the ﬁrst guideline article [1], we reported speciﬁcity
and sensitivity of skin biopsy for the diagnosis of SFN
based on an unpublished meta-analysis of 161 patients
from 9 studies, two of them performed with confocal
microscope technique. The same year, Koskinen et al.
[28] reported similar values for idiopathic or secondary
SFN.
In the last few years, two studies [7,51] focused on the
analysis of the diagnostic yield of skin biopsy in SFN
using the receiver operating characteristic (ROC) curve
that graphically describes the discrimination threshold
of sensitivity versus speciﬁcity or true positives versus
false positives. The IENF density cutoﬀs of 7.63/mm
and £8.8/mm at distal leg were associated with speci-
ﬁcity of 90% and 79.6% and sensitivity of 82.8% and
77.2%, respectively. One study [17] compared three
statistical methods: (i) Z-scores, calculated from multi-
ple regression analysis, which cut-oﬀ values were esti-
mated for each patient and adjusted for age and gender;
(ii) ﬁfth percentile, which cut-oﬀ value was 6.7 IENF/
mm; and (iii) ROC analysis, which cut-oﬀ value was
10.3 IENF/mm. Highest speciﬁcity was obtained with
Z-scores (98%) and ﬁfth percentile (95%), which had
lower sensitivity (31% and 35%, respectively) compar-
ing to the ROC analysis that showed speciﬁcity of 64%
and sensitivity of 78%. The authors emphasized that
the diagnostic yield of skin biopsy depends on how the
reference and cut-oﬀ values have been assessed. In most
studies, skin biopsy has been used to investigate
patients with SFN either idiopathic or associated to
diﬀerent conditions, including diabetes, infectious dis-
eases, systemic connective tissue disorders, and genetic
diseases. However, no study was designed to demon-
strate whether skin biopsy can be useful to identify the
etiology of SFN. Therefore, no data on this issue are yet
available. More details are provided in Appendix 1.
Assessment of morphological changes
Morphological changes of IENF and dermal nerve
ﬁbers (swellings, weaker immunoreactivity, crawler)
were reported as common ﬁndings in SFN but were also
present to a lesser extent in healthy individuals [53,54].
In three other studies evaluating SFN of diﬀerent
Table 1 Intraepidermal nerve ﬁbre (IENF) density at the ankle: nor-
mative values for clinical use (reproduced from Bakkers et al., Neu-
rology, with permission)
Age
(years)
Females (n = 97) Males (n = 91)
0.05 Quantile
values per
age span
Median
values per
age span
0.05 Quantile
values per
age span
Median
values per
age span
20–29 6.7 11.2 5.4 9.0
30–39 6.1 10.7 4.7 8.4
40–49 5.2 9.9 4.0 7.8
50–59 4.1 8.7 3.2 7.1
60–69 3.3 7.9 2.4 6.3
‡70 2.7 7.2 2.0 5.9
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etiologies, isolated morphological abnormality with
normal IENF densities were noted in 29.1%, 20%, and
25% of cases [55–57]. Similar results were reported in
62 patients with sensory neuropathy, 29% of whom had
abnormal morphology but normal IENF density [58].
More details are provided in Appendix 1.
Recommendations
Skin biopsy with linear quantiﬁcation of IENF density
is a reliable and eﬃcient technique to conﬁrm the clin-
ical diagnosis of SFN (Recommendation Level A). This
conclusion derives from the examination of studies
involving homogeneous groups of patients with possi-
ble SFN. However, as the deﬁnition of SFN varied in
the diﬀerent studies, we could not provide the range of
sensitivity and sensibility values.
Immunohistochemical technique does not seem to
inﬂuence the diagnostic eﬃciency in diagnosing SFN.
However, data from comparative studies using the two
techniques in homogeneous groups of patients with
SFN are not available yet and are warranted.
For diagnostic purposes, we recommend quantitative
assessment of IENF density with appropriate quality
controls, which includes all the steps of the procedure,
in particular the aspect of intra- and interobserver
ratings. The diagnosis of SFN with skin biopsy should
be based on the comparison with normative reference
values adjusted by age (Recommendation Level A)
and possibly gender (Recommendation Level B).
Diﬀuse IENF swellings, especially if large, may have
a predictive value to the progression of neuropathy
(Recommendation Level C). Further studies to inves-
tigate the ability of skin biopsy in diﬀerentiating
patients with symptoms mimicking SFN are warranted.
Correlation between IENF density and other
measures of neuropathy
Correlation with clinical measures
In the last 4 years, a number of studies investigating
the correlation between skin biopsy and clinical scales
have been published. However, there are no deﬁnite
diagnostic criteria nor validated scales for SFN.
Therefore, we report here available comparative data
between skin biopsy, clinical ﬁndings, and various
neuropathy scales.
Intraepidermal nerve ﬁber density was closely related
to, and predicted, pin sensation loss in 106 subjects with
idiopathic SFN [47]. Amongst subjects with diabetic
neuropathy, IENF density progressively declined with
increased severity of clinical neuropathy, measured
using the Neurological Disability Score [59–61]. An-
other study in diabetic subjects with normal nerve
conduction studies found a negative correlation be-
tween IENF density at the lower leg and the Neurop-
athy Impairment Score [62].
A recent study [16] investigated three groups of
patients with sarcoidosis: (i) patients without SFN
symptoms (n = 14), (ii) patients with SFN complaints
and normal IENF density ﬁndings (n = 39), and
(iii) patients with SFN complaints and abnormal IENF
density values (n = 19). The authors found that sig-
niﬁcantly more SFN-related symptoms (as reported by
an SFN-related symptoms inventory questionnaire)
were present in patients with abnormal IENF
density, with a gradual transition between the three
subgroups.
In two studies investigating patients with systemic
lupus erythematosus, IENF density negatively corre-
lated with cutaneous vasculitis and disease activity
[63,64]. Conversely, in HIV-associated neuropathy,
there was no correlation between distal IENF density
and Total Neuropathy Score [65], although a baseline
reduction in IENF density predicted the risk of devel-
oping neuropathy symptoms over a 2.9-year period,
which was 14-fold higher in patients with IENF density
of less than 10 ﬁbers/mm [66]. Another study failed to
demonstrate a relationship with the Neuropathy
Symptoms Score [17].
Intraepidermal nerve ﬁber density was lower in dia-
betic neuropathy patients with pain compared to those
without [45,51,59], whereas no correlation was previ-
ously found in another study [42]. In HIV-associated
sensory neuropathy, IENF density inversely correlated
with pain severity assessed with both VAS and the
Gracely Pain Score [65]. Conversely, a previous study
found a correlation only with patients and doctors
evaluation scores [67] and another [56] showed that
assessment of IENF density could not diﬀerentiate be-
tween symptomatic or asymptomatic HIV neuropathy
patients. In patients with pure SFN of mixed etiology,
IENF density was lower in those with pure spontaneous
pain than those with pure evoked pain, but it did not
correlate with its intensity [7].
Correlation with sensory nerve conduction studies
Concordance between sural sensory nerve action
potential (SNAP) amplitude and IENF density was
investigated in several studies with diﬀerent results. This
is probably in keeping with the diﬀerent types of neu-
ropathy examined (i.e. large or mixed ﬁber vs small ﬁber)
with most studies focusing on SFN. We have previously
reported [1] that concordance between sural SNAP
amplitude and IENF density was found in patients with
clinical impairment of large nerve ﬁbers, whereas skin
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biopsy appeared more sensitive than sural sensory NCS
in diagnosing SFN. Recent studies strengthened this
assumption. In 67 patients with pure SFN, sensory NCS
were normal and IENF density at distal leg was reduced
in 88% of cases [7]. However, a recent study [68] con-
ﬁrmed the previously observed linear correlation be-
tween medial plantar SNAP amplitude and IENF
density in patients with SFN [14] and found a correla-
tion with digital plantar near-nerve needle sensory nerve
conduction study (NCS) at the multivariate analysis.
These ﬁndings suggest that most large sensory ﬁbers can
be impaired in distal segments in some patients with
clinical picture of pure SFN. Therefore, clinically pure
SFN can be part of a mixed sensory neuropathy. More
details are provided in Appendix 1.
Correlation with small fiber-related evoked potentials
Few studies have examined the relationship between
skin biopsy and neurophysiological tests for assessing
small ﬁber function and most of the available data
come from single case reports. More details are pro-
vided in Appendix 1.
Correlation with quantitative sensory testing (QST) and
autonomic nervous system testing
Psychophysical assessment of thermal, heat-pain, and
vibratory thresholds provides information on A¶ and
C, and Aß ﬁbers, respectively. However, the correlation
between QST and IENF density remains controversial.
More details are provided in Appendix 1.
Although IENF have somatic functions, several
studies investigated their relationship with autonomic
dysfunction in neuropathy of diﬀerent etiology. Clinical
signs of dysautonomia and abnormal veno-arteriolar
reﬂex and vasodilatation induced by local heating,
reﬂecting impaired skin axonal reﬂexes carried by
somatic C-ﬁbers, were found in about 70% of patients
with pure SFN [7]. Another study did not ﬁnd any
correlation between IENF density and measures of
autonomic function in SFN [51].
Correlation with sural nerve biopsy
In the last 4 years, no further study investigated the
correlation between skin and nerve biopsy. Therefore,
we refer to the recommendations proposed in the ﬁrst
EFNS skin biopsy guidelines [1].
Recommendations
Decreased IENF density reliably indicates the presence
of SFN (Recommendation Level A). However, corre-
lation between IENF density, validated measures of
neuropathy severity, and clinical disability needs fur-
ther evaluation in patients with neuropathy of speciﬁc
etiologies (Recommendation Level C).
The relationship between IENF density and neuro-
pathic pain is more complex than a simple inverse
correlation. Lower IENF density may be associated
with the presence of neuropathic pain, especially in pure
SFN (Recommendation Level B), but it does not cor-
relate with the intensity of pain.
Quantiﬁcation of IENF density can better assess the
diagnosis of SFN than sural NCS and sural nerve
biopsy (Recommendation Level A). Concordance
between IENF quantiﬁcation and medial plantar SNAP
amplitude in patients with normal sural NCS suggests
that distal sensory nerve recording might be more
sensitive than sural NCS in the diagnosis of sensory
neuropathy (Recommendation Level C).
Intraepidermal nerve ﬁbers density correlates with
psychophysical examination of small ﬁber dysfunction
using thermal and nociceptive detection thresholds
(Recommendation Level A), but correlation with spe-
ciﬁc sensation (e.g. cooling, warm, heat-pain) remains
uncertain (Recommendation Level C). Correlation with
autonomic dysfunction needs more extensive validation
(Recommendation Level C).
Further studies are required to determine the relative
diagnostic utility of non-conventional neurophysiolog-
ical methods to investigate small ﬁber function [e.g.
Laser Evoked Potentials (LEPs), Contact Heat Evoked
Potentials (CHEPs) and pain-related somatosensory
evoked potentials (PREPs)] and their correlation with
IENF density.
Skin biopsy as a measure of outcome
Several prospective studies and case reports have
investigated the relationship between skin innervation
and outcome. Overall, they showed that a lower IENF
density is associated with a higher risk of progression to
neuropathy [59,66] and that IENF regeneration posi-
tively correlated with decreased neuropathic pain
intensity [69]. Studies measuring the rate of IENF
regeneration following capsaicin chemical denervation
showed that it is slower in patients with diabetes or HIV
without signs or symptoms of neuropathy [70,71]. More
details are provided in Appendix 1.
Recommendations
In SFN, the reduction of IENF density over time can
be used as an index of progression of neuropathy
(Recommendation Level A). In HIV patients without
neurological symptoms, skin biopsy with quantiﬁcation
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of the IENF densities may predict the risk of progres-
sion to symptomatic HIV neuropathy (Recommenda-
tion Level B). Regeneration of IENF may be associated
with recovery of neuropathic pain and sensory symp-
toms (Recommendation Level C). Skin biopsy may be
considered as an endpoint in future neuroprotective
neuropathy trials (Recommendation Level B).
EFNS/PNS standards
Skin biopsy with quantiﬁcation of IENF density is a
reliable technique to diagnose SFN. For diagnostic
purposes, we endorse 3-mm punch skin biopsy at the
distal leg (10 cm above the lateral malleolus), and
quantiﬁcation of linear IENF density in at least three
50-lm thick sections per biopsy, ﬁxed in 2% PLP or
Zambonis solution, by immunohistochemistry using
rabbit polyclonal anti-PGP 9.5 antibodies, using either
bright-ﬁeld microscopy or immunoﬂuorescence with or
without confocal microscopy. Appropriate normative
data from healthy subjects matched for age and gender
should be always used.
We strongly recommend training in an established
cutaneous nerve laboratory before performing and
processing skin biopsies in the diagnosis of SFN.
Quality control should include all the steps of the
procedure, in particular the aspect of intra- and inter-
observer ratings for qualitative assessments and for
quantitative analysis of epidermal densities.
Proposal for new studies
Normative reference studies reporting age- and gender-
matched values of IENF density at proximal and distal
sites using indirect immunoﬂuorescence technique with
and without confocal microscopy are warranted. These
studies should be collaborative and designed to com-
pare the diagnostic yield of this technique with that of
bright-ﬁeld microscopy in patients with SFN.
A clinimetric approach should be used to assess the
correlation between skin innervation and the clinical
symptoms and signs of SFN. Such studies should
include patients whose clinical picture mimics that of
SFN, to deﬁnitely assess speciﬁcity and sensitivity of
skin biopsy in the diagnosis of this type of neuropathy.
A consensus deﬁnition of SFN is needed to plan new
studies that will determine the sensitivity and speciﬁcity
of skin biopsy and other potential diagnostic strategies.
The reliability of already tested or new methods to
quantify the density of nerve ﬁbers in the sub-epidermal
dermis and autonomic structures (e.g. sweat gland
nerve, erector pili muscle, and vessels) should be con-
ﬁrmed by further studies in patients with homogeneous
types of peripheral neuropathy, including SFN. Cor-
relative studies between skin biopsy, autonomic tests,
and non-conventional neurophysiologic tools are also
warranted.
Lastly, further studies should focus on the ability of
skin biopsy to detect early changes of nerve ﬁbers that
predict the progression of neuropathy and that assist in
assessing nerve degeneration and regeneration rates
over time, to conﬁrm the potential usefulness of the
technique as an outcome measure in clinical practice
and research.
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Appendix 1
Details provided in the EFNS website
Methodological issues
How to perform skin biopsy and choice of biopsy
location
To evaluate receptors and myelinated ﬁbers, glabrous
skin biopsies are usually obtained from the tip or lateral
aspect of the 2nd or 3rd ﬁnger. Skin biopsy can be
performed in other body sites to reveal a uni-lateral
neural process. However, a control sample may be
needed from the contralateral non-aﬀected side for
comparison of the innervation density [1].
Tissue preparation
Formalin ﬁxation should be avoided for possible arte-
facts causing a more fragmented appearance of nerve
ﬁbers [2,3], though it did not aﬀect the measurement of
the innervation density [4,5].
In most studies using bright-ﬁeld immunohisto-
chemistry and immunoﬂuorescence without confocal
microscopy, at least three sections of 50 lm thickness
from each biopsy were examined. In confocal micros-
copy studies, usually sections of 50–100 lm thickness
were immunostained. Confocal microscopy allows
analysing double, triple, and even quadruple stained
sections. PGP 9.5 and collagen IV double stained sec-
tions were used to visualize axons and basement
membrane in order to trace intraepidermal nerve ﬁbers
(IENF) from the site where they penetrate the basement
membrane to their endings.
IENF morphometry and measurement reliability
Intra- and interobserver variability on IENF counts has
been examined in several studies. Goransson et al. [6]
assessed blindly the intraobserver (number of sections,
100) and interobserver (number of sections, 58) reli-
ability. The mean diﬀerence in IENF by intraobserver
analysis was 0.2 ± 1.2 IENF/mm. The 95% of the
diﬀerence between paired counts was expected to lie
within standard deviation, which is deﬁned as the limit
of agreement. For intraobserver variability, this limit of
agreement was )2.2 to 2.6 IENF/mm. The interobserver
variability was higher than the intraobserver variability,
with a mean diﬀerence in IENF of 0.4 ± 1.5 ﬁbers/mm.
The limit of agreement was )3.4 to 2.6 IENF/mm. Most
recently, Bakkers et al. [7] provided a blind assessment
of intra- and interobserver variability (50 slides, 150
sections) within the Maastricht (NL) laboratory and the
interlaboratory variability (30 slides, 90 sections) be-
tween the skin biopsy laboratories of Maastricht, Ferr-
ara (I), and Milan (I). Test–retest reliability was
determined using the weighted kappa-statistic measures
[8]. The authors reported good intraobserver reliability
values (weighted kappa = 0.95 and 0.90) and interob-
server scores (0.94). The interlaboratory agreement
values (weighted kappa) between three laboratories
were: Maastricht–Milan = 0.78; Maastricht–Ferr-
ara = 0.83; Milan–Ferrara = 0.91.
The skin blister is an alternative technique to assess
the epidermal innervation density [9]. Blisters are ob-
tained by applying to the skin surface a suction capsule
with single or multiple 2 or 3 mm holes depending upon
the number and size of samples desired. A negative
pressure induces the epidermis to separate at the der-
mal–epidermal junction without damaging the base-
ment membrane and the underlying capillary loops.
The application of a 3 mm tape disk (3M Tegaderm, St
Paul, MN, USA) on the area to be blistered prevents
the blister roof from overstretching, facilitates its
removal and ﬂattens it for processing. After removing
the capsule, the blister roof is excised, ﬁxed, and im-
munostained. Panoutsopoulou et al. [10] compared the
reliability of IENF quantiﬁcation per skin surface area
(IENF/mm2) using confocal immunoﬂuorescence with
the blister method.
Quantification of sweat gland innervation
The quantiﬁcation of sudomotor nerve ﬁbers is tech-
nically challenging because of the complex three-
dimensional structure of the sweat glands. Diﬀerent
methods have been proposed but none has been stan-
dardized [11]. A novel method using an unbiased ste-
reologic technique has been recently proposed [12]. The
authors examined blindly 30 diabetic neuropathy pa-
tients and 64 healthy subjects ﬁnding a signiﬁcant dif-
ference between groups. The density of sweat gland
nerve ﬁbers at the distal leg of diabetic patients de-
creased as the Neuropathy Impairment Score in the
Lower limbs worsened (P < 0.001) and was concor-
dant with symptoms of reduced sweat production
(P < 0.01). In a further work, the authors reported a
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signiﬁcant correlation between the stereologic unbiased
method and a new automated technique for quantiﬁ-
cation of sudomotor nerve ﬁbers, and showed that the
descriptive semiquantitative approach has a poor inter-
and intraobserved reliability [13].
Diagnostic yield of skin biopsy
In the last few years, several studies conﬁrmed that the
reduction of IENF density is useful to diagnose small
ﬁber neuropathy (SFN). In two studies including 185
patients with symptoms or signs suggestive of SFN, 76
patients had reduced IENF densities at the distal leg,
and the reduction of IENF was more severe in patients
with large-ﬁber nerve involvement [14,15]. In 14 out of
17 patients with non-length dependent SFN/ganglion-
opathy and early involvement of the face, trunk or
proximal limbs, skin denervation was equal to or more
prominent in the thigh than in the calf [16], conﬁrming
previous ﬁndings [17]. In patients with diabetes mellitus
but without clinical evidence of neuropathy, the IENF
density at the distal leg was signiﬁcantly lower com-
paring to controls [18,19]. Among 101 patients of ad-
vanced HIV infection with CD4+ cell count <300
cells/mm3 and exposure to nucleoside analogue anti-
retroviral therapy for ‡15 consecutive weeks in the past,
15.5% of patients had mild denervation at the distal leg
and 23.2% had severe denervation at both distal and
proximal thigh [20]. In SFN associated to vasculitis,
eosinophilia, and celiac disease, reduced IENF density
was found in 100%, 83.3% and 62.5% of patients,
respectively [21–23]. Tseng et al. [24] investigated 45
consecutive patients with systemic lupus erythematosus
(21 with active lupus and 20 with neuropsychiatric
syndrome) ﬁnding that 82.2% of patients had reduced
IENF densities, and that IENF density inversely cor-
related with the activity of the disease and with small
ﬁber sensory symptoms and signs. Based on clinical and
skin biopsy ﬁndings, three cross-section studies inves-
tigated SFN in systemic lupus erythematosus, primary
Sjo¨gren syndrome, and rheumatic arthritis reporting
abnormal IENF densities in 13%, 3%, and 4% of pa-
tients, respectively [25–27]. Laaksonen et al. [28] com-
pared women carrying Fabrys disease mutation (83.3%
symptomatic) with healthy controls and found that
27.3% of them had abnormal IENF densities.
Two studies focused on the analysis of the diagnostic
yield of skin biopsy in SFN using the receiver operating
characteristic (ROC) approach that graphically de-
scribes the discrimination threshold of sensitivity versus
speciﬁcity or true positives versus false positives. Vlck-
ova-Moravcova et al. [29] studied a group of 58 pa-
tients with pure SFN and 37 healthy subjects. They
reported that the cut-oﬀ IENF density of £8.8/mm was
associated with a sensitivity of 77.2% and a speciﬁcity
of 79.6% [maximum likelihood estimates 88% (78–93)].
In the same group of SFN patients, the cut-oﬀ density
of 7.25% subepidermal nerve ﬁbers (expressed as per-
cent of the subepidermal area of the size 200 · 50 lm
adjacent to the dermal-epidermal junction) had a sen-
sitivity of 78.2% and a speciﬁcity of 79%. Taking both
IENF and subepidermal nerve ﬁber densities together,
the diagnostic sensitivity in pure SFN was further im-
proved to 86%.
Devigili et al. [30] investigated 67 patients with pure
SFN (from a cohort of 124 patients with sensory neu-
ropathy) diagnosed by the presence of at least two
abnormal results on clinical examinations, quantitative
sensory testing (QST), and skin biopsy. The authors
reported sensitivity of 88%, speciﬁcity of 88.8%, posi-
tive predictive value of 89.4%, and negative predictive
value of 87.5%. The cut-oﬀ of 7.63 IENF/mm at the
distal leg was associated with speciﬁcity of 90% and
sensitivity of 82.8% comparing 110 patients with
painful neuropathy and 47 healthy subjects. The au-
thors found a normal IENF density in 16 patients with
symptoms mimicking a possible SFN (psychiatric ill-
ness, lumbar stenosis, venous insuﬃciency).
Nebuchennykh et al. [31] compared the diagnostic
yield of skin biopsy for diagnosing SFN (45 patients
and 134 healthy subjects) using three statistical meth-
ods: 1) Z-scores, calculated from multiple regression
analysis, which cut-oﬀ values were estimated for each
patient and adjusted for age and gender; 2) ﬁfth per-
centile, which cut-oﬀ value was 6.7 IENF/mm; and 3)
ROC analysis, which cut-oﬀ value was 10.3 IENF/mm.
Highest speciﬁcity was obtained with Z-scores (98%)
and ﬁfth percentile (95%), which had lower sensitivity
(31% and 35%, respectively) comparing to the ROC
analysis that showed speciﬁcity of 64% and sensitivity
of 78%. The authors emphasized that the diagnostic
yield of skin biopsy depends on how the reference and
cut-oﬀ values have been assessed.
Assessment of morphological changes
Two studies analyzed the morphological changes in
patients with SFN and reported that IENF and dermal
nerve ﬁber swellings, weaker axonal immunoreactivity,
and a unique type of IENF (crawler) were common
ﬁndings [32,33]. However, some of these ﬁndings were
also common to a lesser extent in normal individuals
[32]. In three other studies evaluating SFN of diﬀerent
etiologies, isolated morphological abnormality with
normal IENF densities were noted in 29.1%, 20%, and
25% of cases [22,34,35]. Similar results were reported in
62 patients with sensory neuropathy, 29% of whom had
abnormal morphology but normal IENF density [36].
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One further study provided a blind assessment of IENF
swellings in 28 patients with pure SFN [37]. The
amount of axonal swelling was semi-quantitatively
scored as large, medium, or small. Repeated biopsy
showed that patients with large swellings had a signiﬁ-
cant reduction in IENF density compared to those
without swellings. However, the retrospective design of
the study, the variability in timing between biopsies,
and the absence of a control group limited the inter-
pretation of the results.
Correlation between IENF density and other
measures of neuropathy
Correlation with sensory nerve conduction studies
Patients with mixed sensory neuropathy associated to
diabetes or HIV showed a signiﬁcant direct correlation
between sural sensory nerve action potential (SNAP)
amplitude and IENF density [20,38]. A similar rela-
tionship was found in a large study involving 210 pa-
tients with neuropathy of diﬀerent aetiology [31]. One
study found no correlation between IENF density and
sural nerve SNAP amplitude, but a good correlation of
SNAP amplitude with the density of the subepidermal
nerve ﬁber [29]. In the prospective study of impaired
glucose tolerance (IGT)-associated neuropathy, the
authors found a positive correlation between the degree
of IENF regeneration and the increase in sural SNAP
amplitude, although there was no baseline relationship
between the two [39].
Correlation with small fiber related evoked potentials
Few studies have examined the relationship between
skin biopsy and neurophysiological tests for assessing
small ﬁber function, and most of the available data
come from single case reports [40–43]. In a subgroup of
10 patients with pure SFN and decreased IENF at the
distal leg, laser evoked potentials did not diﬀer com-
paring with 18 healthy subjects [30]. Two studies
examined contact heat evoked potentials (CHEP) in 66
neuropathy patients. Both found a positive correlation
between IENF density and the amplitude of Ad-related
potential [44,45]. One study showed a correlation be-
tween IENF density and pain-related electrically
evoked potential (PREP) amplitudes and latencies [46].
Correlation with QST and autonomic nervous system
testing
Psychophysical assessment of thermal, heat-pain, and
vibratory thresholds provides information on A¶ and C,
and Aß ﬁbers, respectively. However, the correlation
between QST and IENF density remains controversial.
IENF density inversely correlated with both cold and
warm/heat detection thresholds [19,30,38], whereas
other studies showed a closer correlation with warm and
heat-pain thresholds [24,29,47–52] than with cooling
threshold [53–55]. Moreover, two studies suggested a
closer correlation with cold than heat detection [20,56].
A correlation with vibratory detection threshold was
more likely when patients have clinical and electro-
physiological evidence of large ﬁber neuropathy [20,56].
Skin biopsy as a measure of outcome
Several prospective studies and case reports have
investigated the relationship between skin innervation
and outcome. In patients of asymptomatic HIV infec-
tion with or without neurological signs, a lower IENF
density was associated with a higher risk of progression
to symptomatic HIV neuropathy [57]. A progressive
reduction in IENF densities at the foot dorsum corre-
lated with the severity of the neuropathy in diabetic
patients [38,58]. Boucek et al. [59,60] investigated skin
innervation in 18 patients with type 1 diabetes before
and after pancreas/kidney transplantation, but did not
ﬁnd signiﬁcant changes. In a 1-year study of diet and
exercise in patients with IGT and neuropathy, skin
reinnervation (increased IENF density at the proximal
thigh) positively correlated with decreased neuropathic
pain intensity [39]. Studies measuring the rate of IENF
regeneration following capsaicin chemical denervation
showed that it is slower in patients with diabetes or HIV
without signs or symptoms of neuropathy compared to
healthy subjects [61]. In case reports of toxic-related
painful neuropathy caused by linezolid [62] or hypo-
thyroidism [63], the authors showed that the regenera-
tion of IENF was associated with recovery of thermal
threshold and neuropathic pain.
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